
    
      In the present study, investigator plan to use a double-blind, between-subject placebo
      controlled design.Firstly, all healthy male subjects' autistic trait levels will be assessed
      by the Autism Spectrum Quotient (ASQ) and only subjects with higher or lower ASQ score will
      be recruited in the next experiment and divided into high and low subgroup. Then, subjects
      are randomly assigned to receive either intranasal administration of oxytocin (24 IU) or
      placebo. 45 min later, subject need to complete an attentional bias task named rapid serial
      visual presentation (RSVP) task in fMRI scanner.
    
  